JARDIANCE®
Sponsors
Boehringer Ingelheim, Pharma Nueva
Conditions
Diabetes Mellitus, Type 2HealthyHealthy VollunteerHeart FailureKidney Disease, Chronic
Phase 1
A Bioequivalence Study of Two Formulations of 10-mg Empagliflozin Tablets in Healthy Thai Volunteers Under Fasting Conditions
Not yet recruitingNCT06308679
Start: 2024-05-28End: 2024-06-07Target: 28Updated: 2024-03-13
A Study in Healthy Men to Compare the Amount of Vicadrostat and Empagliflozin in the Blood When Taken Separately and Together
CompletedNCT07035457
Start: 2025-07-02End: 2025-08-15Updated: 2025-08-20
Unknown Phase
Daily Use of JARDIANCE® Tablets in Japanese Elderly Patients With Type 2 Diabetes Mellitus
CompletedNCT02367131
Start: 2015-02-24End: 2016-09-27Updated: 2024-03-08
Jardiance® Post Marketing Surveillance (PMS) in Korean Patients With Chronic Heart Failure
CompletedNCT05236673
Start: 2022-07-28End: 2025-04-30Updated: 2025-05-16
Post Marketing Surveillance (PMS) of JARDIANCE in Chronic Heart Failure (CHF)
CompletedNCT05262764
Start: 2022-04-15End: 2024-06-28Updated: 2026-03-24
JARDIANCE® Post Marketing Surveillance in Korean Patients With Chronic Kidney Disease (CKD)
CompletedNCT06287073
Start: 2024-03-29End: 2025-04-30Updated: 2026-01-30
Post Marketing Surveillance of JARDIANCE in Chronic Kidney Disease
Active, not recruitingNCT06527846
Start: 2024-10-22End: 2027-03-31Updated: 2026-03-19